Last Updated: June 23, 2026

ROCURONIUM Drug Patent Profile

Name: ROCURONIUM Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

When do Rocuronium patents expire, and when can generic versions of Rocuronium launch?

Rocuronium is a drug marketed by Aspiro, Caplin, Eugia Pharma, Fresenius Kabi Usa, Gland, Hikma, Hospira, Knack, Mankind Pharma, Meitheal, Mylan Institutional, Piramal Critical, Prinston Inc, Rising, Sagent Pharms Inc, Sandoz, Shandong, Steriscience, Tamarang, Teva Pharms, West Ward Pharm Corp, and B Braun Medical. and is included in twenty-three NDAs. There is one patent protecting this drug.

The generic ingredient in ROCURONIUM is rocuronium bromide. There are eleven drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the rocuronium bromide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Rocuronium

A generic version of ROCURONIUM was approved as rocuronium bromide by HOSPIRA on November 26^th, 2008.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for ROCURONIUM?
What are the global sales for ROCURONIUM?
What is Average Wholesale Price for ROCURONIUM?

Summary for ROCURONIUM

US Patents:	0
Applicants:	22
NDAs:	23
Drug Prices:	Drug price information for ROCURONIUM
What excipients (inactive ingredients) are in ROCURONIUM?	ROCURONIUM excipients list
DailyMed Link:	ROCURONIUM at DailyMed

Drug patent expirations by year for ROCURONIUM

US Patents and Regulatory Information for ROCURONIUM

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun Medical	ROCURONIUM BROMIDE	rocuronium bromide	SOLUTION;INTRAVENOUS	219108-001	Oct 24, 2025		RX	Yes	Yes	11,998,605	⤷ Start Trial	Y			⤷ Start Trial
Shandong	ROCURONIUM BROMIDE	rocuronium bromide	INJECTABLE;INJECTION	215684-001	Jul 12, 2024	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Sagent Pharms Inc	ROCURONIUM BROMIDE	rocuronium bromide	INJECTABLE;INJECTION	091458-001	Jul 28, 2010	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.